Clinical Ink Acquires Digital Artefacts

Global clinical trial data and technology company Clinical Ink has announced its acquisition of Digital Artefacts, a digital technology company that specializes in data capture for complex cognitive, behavioral, and physiological research.

“Data derived from Digital Artefacts can now increase the richness of our partners’ study data through the convergence of passive and active digital assessments,” said Clinical Ink CEO Ed Seguine. “Their wearables and sensors acumen provides instrumented data collection that complements our existing products and solutions.”

The combination of the two companies provides other benefits as well, including scientifically validated neurocognitive assessment and research tools, combination of standardized eCOA sales, trial-specific remote active and passive behavioral assessment, precision real world data and insights, expertise in creating clinically relevant novel digital endpoint data, and scaled delivery capabilities.

Having access to these capabilities helps Clinical Ink expand its reputation as a trusted global partner in digital source data capture and eCOA, furthering the company’s therapeutic-area-specific approach to study design and data certainty from source to submission.

Digital Artefacts Co-founder, President, and General Manager Joan Severson expressed excitement about the acquisition: “Our digital endpoint solutions, combined with strong data science, provide expertise that has been foundational with industry recognized partners and top pharma. We are very excited to join Clinical Ink and enhance the seamless data collection, cognitive and behavioral assessments, and quantitative outcomes for even the most complex studies.”

Read the full press release here.